Pseudohypoparathyroidism comprises a group of rare disorders in which the body shows a reduced biological response to the action of parathyroid hormone (PTH) in target tissues, particularly in the kidneys, producing a biochemical profile that mimics hypoparathyroidism despite elevated PTH levels. The functional result is a condition of “peripheral hypoparathyroidism”, characterized by a tendency toward hypocalcemia and hyperphosphatemia due to reduced phosphaturia and impaired renal activation of vitamin D, with a consequent reduction in intestinal calcium absorption. Clinically, pseudohypoparathyroidism lies at the intersection between calcium-phosphate endocrinology and the genetics of signaling pathways mediated by G protein-coupled receptors.
The expression “PTH resistance” should be understood mechanistically: PTH may be produced normally, but signaling downstream of its receptor is attenuated or disrupted. In many forms, resistance is not limited to PTH but may involve other hormones that use similar signaling pathways, resulting in a multisystem phenotype that includes abnormalities of growth, energy metabolism, and characteristic skeletal signs. Diagnosis therefore involves more than recognizing hypocalcemia with elevated PTH. It requires reconstruction of the hormonal resistance profile and the clinical-genetic context that guides prognosis, follow-up, and treatment.
Pseudohypoparathyroidism is considered a rare disorder, with prevalence estimates varying among studies and registries, partly because of its phenotypic heterogeneity and the often prolonged time required for recognition. Its true epidemiology is probably underestimated because the disorder may present during childhood with nonspecific signs or initially incomplete biochemical abnormalities, and because some forms are associated with an “incomplete” clinical phenotype in which PTH resistance develops gradually over time. In many case series, diagnosis is established during childhood or adolescence, but first identification during adulthood is not uncommon, particularly when the disorder presents as episodic hypocalcemia or as an incidental laboratory finding during the evaluation of cramps, paresthesias, or seizures.
A distinctive epidemiological feature is that a substantial proportion of the risk is not associated with environmental factors, but with the transmission of genetic variants or epigenetic alterations in imprinted loci involved in signaling mediated by Gsα and the production of cAMP. In these conditions, the main “risk factor” is family history, although the inheritance pattern may be complex because of imprinting, which means that the same variant can produce different clinical phenotypes depending on the parent from whom it is inherited. This concept has practical implications: familial clustering may be present, but diagnosis may not be straightforward when relatives display different or less evident phenotypes.
The risk profile also includes clinical features that, although not causal, increase the pre-test probability of PTH resistance. The presence of brachydactyly, short stature, a rounded face, superficial ectopic ossifications, and early weight gain or a tendency toward childhood-onset obesity are findings that make a disorder of the Gsα/cAMP/PKA pathway more likely than “primary” hypoparathyroidism. In some subtypes, abnormalities of other endocrine axes, particularly mild resistance to TSH or GH deficiency caused by resistance to GHRH, contribute to the epidemiological profile because they lead patients to clinical evaluation through different pathways, including neonatal screening, growth monitoring, and metabolic assessment.
The absence of a dominant environmental factor does not mean that the clinical context is irrelevant. The severity and likelihood of complications depend on the duration of hyperphosphatemia, the behavior of the calcium-phosphate product, the quality of therapeutic control, and the presence of comorbidities that increase neurological or renal vulnerability. From this perspective, the “clinical epidemiology” of pseudohypoparathyroidism also reflects the natural history of hormonal resistance that tends to become established over time and can be detected early only by maintaining a high level of attention to phenotypic signs and by interpreting calcium-phosphate biochemistry in an integrated manner.
PTH physiology is based on the rapid regulation of ionized calcium and phosphate through the kidneys and bone, integrated with renal calcitriol production. In the renal proximal tubule, PTH reduces phosphate reabsorption and stimulates the enzyme 1α-hydroxylase, increasing the conversion of vitamin D into its active form and thereby enhancing intestinal calcium absorption. In pseudohypoparathyroidism, the pathophysiological core is impaired signal transduction downstream of the PTH receptor, frequently along the Gsα pathway, with generation of cAMP and activation of PKA. Attenuated renal signaling prevents appropriate phosphaturia and adequate vitamin D activation, producing a biochemical profile that progresses toward hypocalcemia and hyperphosphatemia despite parathyroid hyperstimulation.
From an etiological perspective, many classic forms are associated with the GNAS locus, which encodes the α subunit of the stimulatory G protein and is regulated through tissue-specific imprinting. In some tissues, including the renal proximal tubule, thyroid, gonads, and pituitary gland, functional Gsα expression is derived predominantly from the maternal allele. Consequently, maternally inherited inactivating variants may cause multiple hormone resistance, whereas paternal transmission of the same variant may result mainly in somatic features without PTH resistance. This is a key point in understanding why the same genetic defect can produce different phenotypes within the same family.
In addition to coding-sequence variants, a substantial proportion of cases are caused by epigenetic abnormalities involving loss of methylation in regulatory regions of GNAS, which reduce maternal Gsα expression in imprinted tissues. In this setting, PTH resistance is often predominantly renal, whereas somatic signs may be absent or less pronounced. The pathophysiological concept remains the same: the receptor may be present and capable of binding its ligand, but the intracellular signal does not reach the intensity required to activate appropriate tubular responses.
Pathophysiology also explains the temporal course of the disorder. During the first years of life, hyperphosphatemia with elevated PTH may emerge first, whereas hypocalcemia may develop later, when parathyroid compensation can no longer maintain calcium within the reference range. This progression is consistent with resistance that matures or becomes clinically evident with growth and with changes in mineral balance. At the same time, chronic secondary hyperparathyroidism may produce skeletal consequences, particularly when therapeutic control is inadequate, with increased bone remodeling and possible deformities or bone pain during childhood.
A distinct pathophysiological aspect concerns the associated somatic manifestations, often summarized under the phenotype of Albright hereditary osteodystrophy, which includes brachydactyly and ectopic ossifications. These features do not depend directly on calcium or phosphate levels, but on Gsα function in specific mesenchymal cell lineages and on the regulation of osteoblastic differentiation in extraskeletal tissues. In other words, part of the phenotype is “endocrine” because it results from hormone resistance, whereas another part is “developmental” because it arises from signaling defects in nonendocrine cells. This distinction is essential for understanding why control of the calcium-phosphate product reduces some complications but does not alter the tendency toward heterotopic ossification caused by the underlying signaling defect.
The clinical presentation of pseudohypoparathyroidism primarily reflects the effects of hypocalcemia and hyperphosphatemia, but it is modulated by the presence of somatic signs and any additional endocrine resistance. During medical history taking, symptoms may be intermittent or subtle and may include perioral and distal paresthesias, cramps, muscle spasms, laryngospasm, and seizures in more severe cases. Some patients have few symptoms and are diagnosed following an incidental laboratory finding, whereas in others hypocalcemia becomes apparent during metabolic stress, pubertal growth, interruption of supplementation, or conditions that reduce calcium intake or absorption.
The clinical history may include features that, when considered together, suggest a Gsα signaling disorder. In subtypes with a somatic phenotype, early weight gain, short stature, impaired growth, or mildly abnormal motor developmental milestones may be reported. Some patients experience sleep-disordered breathing or obstructive sleep apnea associated with obesity, with an adverse effect on sleep quality and daytime performance. When TSH resistance coexists, there may be a history of mild hypothyroidism identified early, sometimes through neonatal screening programs.
On physical examination, signs of hypocalcemia include neuromuscular hyperexcitability, Chvostek and Trousseau signs when assessed in appropriate settings, and tremors or muscle contractions. Skeletal examination may reveal brachydactyly with shortened metacarpals, broad hands, and, in some cases, functional joint limitation when periarticular ectopic ossifications are present. Skin examination may reveal hard subcutaneous nodules consistent with superficial ossifications, which often represent a highly informative clinical sign when found in the context of calcium-phosphate abnormalities.
The clinical profile varies considerably among subtypes. In some forms, PTH resistance is the predominant feature and somatic manifestations are minimal. In others, the somatic phenotype is evident and is associated with multiple endocrine resistance, affecting growth, puberty, and energy metabolism. This heterogeneity requires a clinical assessment that is not limited to hypocalcemic tetany but includes a systematic evaluation of growth, body composition, skeletal signs, and the patient’s overall endocrine history.
Clinical suspicion should arise when hypocalcemia is associated with elevated or inappropriately high PTH, particularly in the presence of hyperphosphatemia and in the absence of factors explaining a nonspecific secondary parathyroid response. A patient with hypocalcemic neuromuscular symptoms and laboratory findings consistent with “functional” hypoparathyroidism but elevated PTH represents the typical starting point. During childhood, an important clue is the early detection of hyperphosphatemia with elevated PTH preceding hypocalcemia, as this suggests proximal tubular resistance before compensatory mechanisms become exhausted.
Suspicion increases when somatic signs such as brachydactyly, subcutaneous ossifications, short stature, or early-onset obesity coexist. These features, particularly when present in combination, reduce the likelihood of an acquired disorder and make a defect in the Gsα/cAMP/PKA signaling pathway more plausible. Additional supporting evidence includes a history of other endocrine abnormalities, such as persistently elevated TSH with borderline or normal thyroid hormone levels, or growth deceleration requiring assessment of GH secretion.
Suspicion should also be maintained in adults with an atypical presentation. Intracranial calcifications, cataracts, or neurological symptoms in the context of an abnormal calcium-phosphate product may indicate a long history of suboptimal mineral control. In patients with a complex family history, it is essential to remember that imprinting can obscure a “simple” Mendelian inheritance pattern and that relatives may show different manifestations, with or without PTH resistance.
The diagnostic evaluation must confirm PTH resistance, exclude alternative causes of hypocalcemia with elevated PTH, and define the clinical and molecular subtype, because treatment and follow-up depend on the specific pathophysiology. First-line investigations include measurement of calcium, preferably ionized calcium when available, phosphate, PTH, magnesium, 25-hydroxyvitamin D, renal function, and albumin, together with a medication and nutritional history. Vitamin D deficiency, hypomagnesemia, and chronic kidney disease must be excluded because they can cause secondary hyperparathyroidism and calcium-phosphate abnormalities that partially mimic this condition.
Once a biochemical profile of hypocalcemia, hyperphosphatemia, and elevated PTH has been established in a compatible clinical context, the next step is to distinguish forms of PTH resistance from other causes of hypocalcemia with elevated PTH and to characterize the disorder through an integrated clinical-biochemical and genetic-epigenetic approach. The recommendations of the first international consensus statement on pseudohypoparathyroidism and related disorders emphasize the importance of combining major clinical criteria, biochemical findings, and targeted molecular testing when available.
Diagnostic assessment of PTH resistance
Imaging and instrumental investigations are guided by the clinical presentation. Radiographs of the hands and feet may document brachydactyly and support interpretation of the phenotype. Assessment of subcutaneous or periarticular ossifications may require soft-tissue ultrasonography or dedicated imaging in symptomatic cases. In patients with a long history of hypocalcemia or neurological signs, evaluation for intracranial calcifications may be appropriate, whereas ophthalmological assessment is relevant when lens calcification is suspected. Renal monitoring includes renal function and urinary calcium excretion, because treatment with calcitriol and calcium may increase the risk of hypercalciuria even when the aim is to maintain serum calcium in the low-normal range.
The differential diagnosis includes true hypoparathyroidism, in which PTH is low or inappropriately normal, hypocalcemia caused by vitamin D deficiency, hypocalcemia caused by hypomagnesemia, and hyperphosphatemic conditions caused by renal failure. Elevated PTH, hyperphosphatemia, and preserved renal function, together with phenotypic signs and possible associated endocrine resistance, strongly support PTH resistance. When biochemical findings are inconsistent or appear “mixed”, serial reassessment is essential because resistance may emerge progressively and a single blood sample may not represent the patient’s entire pathophysiological course.
The historical classification of pseudohypoparathyroidism distinguished different forms according to functional tests and phenotype, but advances in genetics and epigenetics have led to an interpretation that is more consistent with the underlying signaling mechanisms. In practical terms, an initial distinction separates forms with a typical somatic phenotype and multiple hormone resistance from those in which PTH resistance predominates and somatic signs are absent or mild. This framework helps predict which endocrine axes should be monitored over time and which complications are more likely to occur.
In the classic model, forms associated with maternally inherited inactivating variants in GNAS are typically associated with PTH resistance and often with additional endocrine resistance, together with possible somatic manifestations such as brachydactyly and superficial ectopic ossifications. When the same defect is inherited from the father, somatic features without PTH resistance may predominate, highlighting the role of imprinting and explaining why the family history may appear discontinuous. In addition, forms associated with imprinting defects of the GNAS locus may predominantly cause renal PTH resistance and are more frequently associated with mild TSH resistance, with variable clinical expression.
A more recent classification proposes grouping these conditions under the term “inactivating PTH/PTHrP signaling disorders”, which includes pseudohypoparathyroidism, pseudopseudohypoparathyroidism, acrodysostosis, and related conditions unified by dysfunction of the Gsα/cAMP/PKA pathway. This approach is useful because it shifts attention from historical labels alone to the underlying mechanism, facilitating systematic assessment of the main clinical domains: PTH resistance, skeletal abnormalities, ectopic ossifications, and multiple endocrine resistance.
Clinical severity does not simply correspond to the serum calcium level at diagnosis. It is determined by the duration of hyperphosphatemia, control of the calcium-phosphate product, the presence of neurological symptoms or seizures, renal vulnerability, and the extent of ectopic ossification when present. In pediatric patients, severity also includes the effects on growth and development, with particular attention to GH deficiency and the functional consequences of brachydactyly and ossifications. A management-oriented clinical classification must therefore integrate biochemical findings, phenotype, the endocrine axes involved, and the risk of organ complications.
Treatment is aimed at correcting the consequences of PTH resistance and reducing symptoms and complications rather than “replacing” a deficient hormone. The central principle is to maintain serum calcium within a safe range, preferably in the low-normal range, reduce hyperphosphatemia, and control secondary hyperparathyroidism without causing hypercalcemia or hypercalciuria. In clinical practice, treatment involves active forms of vitamin D, particularly calcitriol or its analogues, together with calcium supplementation when required, with gradual dose adjustments based on clinical and laboratory findings. The rationale is to partially bypass impaired renal activation of vitamin D and increase intestinal calcium absorption, thereby improving neuromuscular stability and reducing parathyroid stimulation.
Control of phosphate is a crucial objective. Renal resistance to PTH reduces phosphaturia and promotes persistent hyperphosphatemia, which increases the calcium-phosphate product and predisposes to ectopic calcifications in sites such as the basal ganglia and lens. Treatment includes a carefully planned restriction of dietary phosphate and, when biochemical control remains inadequate, the use of phosphate binders selected according to the patient’s clinical profile, while avoiding an excessive calcium load when this may increase the risk of hypercalciuria. Complete normalization of PTH is not a primary therapeutic goal if it requires a potentially harmful increase in serum or urinary calcium, because renal safety is a major determinant of long-term prognosis.
Treatment must also address associated endocrine resistance when present. Resistance to TSH may require thyroid hormone replacement therapy, with monitoring that takes account of the resistance context and the patient’s overall clinical balance. In patients with GH deficiency caused by GHRH resistance, GH therapy may be indicated according to specialist criteria, with growth and metabolic objectives and careful follow-up. The phenotype of early-onset obesity requires an integrated nutritional and behavioral program because cardiometabolic risk may become the predominant determinant of the patient’s natural history even when mineral control is satisfactory.
Ectopic ossifications and skeletal manifestations require a function-oriented approach. Treatment of mineral metabolism does not directly alter the tendency to develop heterotopic ossifications caused by the signaling defect, but it reduces the risk of “metastatic” calcifications associated with an elevated calcium-phosphate product. Management of ossifications includes orthopedic assessment and, in selected cases, targeted interventions for pain or functional limitation, bearing in mind that surgery may not be curative and must be considered cautiously. Rehabilitation and functional adaptation are often more relevant than anatomical correction, particularly when ossifications are multiple or located in critical sites.
Finally, treatment requires education of the patient and family. Awareness of the early symptoms of hypocalcemia, adherence to calcitriol and calcium supplementation, and an understanding of the need for periodic monitoring reduce the risk of acute decompensation. An effective treatment plan balances biochemical correction, complication prevention, and quality of life while avoiding iatrogenic fluctuations that may be more harmful than mild, stable hypocalcemia.
Follow-up must be structured and continuous because PTH resistance may develop and stabilize over time and because treatment with active vitamin D and calcium requires a careful balance between efficacy and safety. Laboratory monitoring includes calcium, phosphate, PTH, magnesium, and renal function, with particular attention to the calcium-phosphate product. During dose titration or after treatment changes, assessments should be performed more frequently. Once stability has been achieved, the interval can be adapted according to individual risk and the history of biochemical fluctuations or symptoms.
Urinary surveillance is essential. Urinary calcium excretion must be monitored because the increased intestinal calcium absorption induced by calcitriol may cause hypercalciuria even when serum calcium remains within the desired range. This risk requires a cautious strategy involving a low-normal serum calcium target, avoidance of excessive calcium supplementation, and periodic assessment of renal function. Depending on the patient’s profile, surveillance for nephrocalcinosis or nephrolithiasis may be appropriate, particularly when urinary calcium excretion is persistently elevated or urinary symptoms are present.
Follow-up should include extended endocrine assessment when suggested by the phenotype. In patients with suspected or documented TSH resistance, thyroid monitoring must be coordinated with replacement therapy when indicated. During childhood, assessment of growth and possible GH deficiency has implications for final height and body composition. Pubertal development and gonadal function should be monitored when clinical signs of dysfunction are present because some forms may be associated with gonadotropin resistance or reproductive disorders.
An important component of follow-up is the assessment of organ complications related to chronic hyperphosphatemia. In the presence of neurological symptoms, headache, movement disorders, or other suggestive signs, targeted assessment for intracranial calcifications may be indicated. Ophthalmological surveillance is relevant when clinical findings suggest lens opacity or visual disturbances. These investigations are not automatically required for every patient but should be tailored according to individual risk and the history of calcium-phosphate product control.
Finally, follow-up must also be functional and preventive. In patients with obesity and cardiometabolic risk, a longitudinal strategy addressing diet, physical activity, and metabolic screening is required. In patients with ectopic ossifications, periodic assessment of joint function and pain permits early rehabilitative intervention. High-quality follow-up integrates mineral control, renal safety, multisystem endocrine monitoring, and long-term support, reducing both biochemical risks and the daily burden of the disease.
Prognosis depends on the accuracy of the etiological assessment, the timeliness of diagnosis, and the quality of calcium-phosphate balance control. When treatment maintains serum calcium within a safe range and controls hyperphosphatemia, neuromuscular symptoms improve and the risk of acute events decreases substantially. Prognosis is nevertheless variable because some forms have a multisystem phenotype with multiple endocrine resistance, early-onset obesity, and skeletal manifestations requiring prolonged multidisciplinary management.
The main complications fall into three domains. The first is neurological and neuromuscular: uncontrolled hypocalcemia may cause tetany, laryngospasm, and seizures, with an adverse effect on quality of life and a risk of hospital admission. The second domain involves “metastatic” ectopic calcifications associated with hyperphosphatemia and an elevated calcium-phosphate product, which may affect intracranial or ocular structures and are more likely when hyperphosphatemia persists and therapeutic control is inconsistent. The third domain concerns renal safety because treatment with active vitamin D and calcium may cause hypercalciuria and, over time, increase the risk of nephrolithiasis or nephrocalcinosis if it is not managed with cautious targets and regular monitoring.
Skeletal consequences depend on the balance between secondary hyperparathyroidism and therapeutic control. In some situations, persistent parathyroid stimulation may increase bone remodeling and promote pain or radiological abnormalities, particularly when diagnosis is delayed. Ectopic ossifications represent a separate issue because they reflect a developmental defect associated with Gsα signaling and may cause functional limitation or pain independently of the quality of mineral control. Management of these manifestations is often prolonged and focused on preserving function rather than completely eliminating the lesions.
In subtypes associated with early-onset obesity and potentially reduced energy expenditure, long-term prognosis is influenced by cardiometabolic risk, which may become clinically predominant. In this setting, calcium-phosphate control is necessary but not sufficient. Prevention of diabetes, dyslipidemia, and cardiovascular complications requires structured and sustained interventions. Similarly, the presence of TSH resistance or GH deficiency affects functional prognosis in terms of growth, body composition, and general well-being, making extended endocrine follow-up essential.
Overall, pseudohypoparathyroidism is a manageable condition with good clinical control in most cases, but it requires a long-term strategy focused on renal safety, prevention of complications caused by hyperphosphatemia, and recognition of multisystem involvement. The best prognosis is achieved when diagnosis is established early, the subtype is accurately defined, and the patient is enrolled in a surveillance program integrating mineral metabolism, endocrine comorbidities, and quality of life.